MEDP vs. NTRA: Medpace vs. Natera Stock Comparison

Company Profile

Medpace (MEDP) and Natera (NTRA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while NTRA is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Medpace (MEDP) reports 18.24%, ranking against industry peers normally.

Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Medpace (MEDP) reports 23.12%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Medpace (MEDP) at 19.97% and Natera (NTRA) at 35.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Natera (NTRA) at 2.81 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

Both Medpace (MEDP) at 0.29 and Natera (NTRA) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Medpace (MEDP) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Medpace (MEDP) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.

On P/S ratio, both Medpace (MEDP) at 6.44 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Measured against book value, both Medpace (MEDP) at 31.23 and Natera (NTRA) at 23.99 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics